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Abstract Genome-wide association studies (GWASs)
have identified 19 susceptibility loci for Alzheimer’s disease (AD). However, understanding how these genes
are involved in the pathophysiology of AD is one of the
main challenges of the “post-GWAS” era. At least 123
genes are located within the 19 susceptibility loci; hence,
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a conventional approach (studying the genes one by one)
would not be time- and cost-effective. We therefore developed a genome-wide, high-content siRNA screening
approach and used it to assess the functional impact of gene
under-expression on APP metabolism. We found that 832
genes modulated APP metabolism. Eight of these genes
were located within AD susceptibility loci. Only FERMT2
(a β3-integrin co-activator) was also significantly associated with a variation in cerebrospinal fluid Aβ peptide
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levels in 2886 AD cases. Lastly, we showed that the underexpression of FERMT2 increases Aβ peptide production by
raising levels of mature APP at the cell surface and facilitating its recycling. Taken as a whole, our data suggest that
FERMT2 modulates the AD risk by regulating APP metabolism and Aβ peptide production.

Introduction
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder. It is the leading cause of dementia worldwide.
Memory loss and cognitive impairments are invariant, early
signs of the AD, whereas hippocampal atrophy is one of
the earliest histological hallmarks of the disease. Two main
lesions are found in the AD brain: the neurofibrillary tangles formed by tau aggregation in neurons, and the senile
plaques formed primarily by aggregated amyloid-β (Aβ)
peptides in the parenchyma. The identification of familial,
AD-linked mutations in the genes for amyloid-β precursor protein (APP) and presenilin (PS1 and PS2) associated
with deregulation of Aβ peptide production suggests that
APP metabolism is at the heart of the disease process. This
hypothesis was recently strengthened by the discovery of
a rare APP mutation that lowered both Aβ peptide production and the AD risk [12]. Lastly, consistent evidence also
suggests that common genetic risk factors for late-onset
AD (LOAD)—including the APOE gene—may be involved
in Aβ clearance in the brain [13]. Taken as a whole, these
observations indicate that Aβ production via the deregulation of APP metabolism should still be considered as a key
pathogenic factor in AD.
Three main proteases (α-, β- and γ- secretases) are
involved in APP processing through (1) the amyloidogenic pathway (β- and γ-secretases), leading to Aβ production, and (2) the non-amyloidogenic pathway (α- and
γ -secretase), which prevents Aβ generation by cleaving
APP within the Aβ sequence [6]. Recently, new δ- and
η-secretase activities have been characterized [1, 26, 28],
indicating that additional APP processing pathways may
exist and may thus modulate Aβ loads. In addition to
secretase activities, APP trafficking in the secretory pathway and APP’s fate are also essential factors in APP metabolism. APP matures in the endoplasmic reticulum and the
Golgi apparatus and is then transported to the cell surface.
Alternatively, APP can reach lysosomal compartments,
where it undergoes proteolytic inactivation [15]. The equilibrium between these two compartments is driven by APP
trafficking and maturation. O- and N-glycosylation are
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prerequisites for making APP available to the secretases at
the cell surface and in the endosomal system, and thus for
Aβ production. In this context, the various mechanisms that
control APP trafficking are being intensively investigated.
However, a large proportion of the key molecular players in
APP trafficking have yet to been characterized.
Interestingly, new susceptibility loci for LOAD have
been identified using genome-wide association studies
(GWASs). One can reasonably assume that some of these
genetic factors are involved in APP metabolism and Aβ
production. However, it is important to bear in mind that
GWAS loci may contain several genes; hence, complex
linkage disequilibrium patterns with the sentinel SNP in
some of these loci may make it impossible to determine
which gene is responsible for the observed signal. Indeed,
there are 123 genes of interest within the 19 genomic risk
regions identified in the International Genomics of Alzheimer’s Project (IGAP) [9]. Even when a causative gene is
eventually characterized, it is often difficult to establish a
link with the pathophysiology of AD on the basis of literature data alone.
Given this context, we are seeking to develop novel,
powerful approaches for empirically testing several
GWAS-identified genes in cell-based or animal models. We
therefore developed a genome-wide, high-content siRNA
screening approach and used it to assess the functional
impact of gene under-expression on APP metabolism.

Methods
HSC assay
We developed HEK293 cells line stably over-expressing a
mCherry-APP695WT-YFP. The modified APP695WT protein
is shown metabolized in the same way as APP695WT [21].
Custom, automatic image processing was used to determine the cell count and the mean fluorescence intensity per
cell for both mCherry and YFP signals in cytoplasm. We
tested the sensitivity of this model by measuring the modulation of intracellular APP fluorescence after treatment with
proteasome inhibitor, γ-secretase inhibitor or transfection
of siRNAs directed against APP and PSEN1 (Supplemental
Fig 1 and Fig. 1c, d). These data demonstrated that both
mCherry and YFP read-outs are markers of APP levels and
APP processing. With an average of 1000 cells analyzed
per well, 100% of test plates (n = 9) were validated with
a β score higher than 3 according to the HCS guideline [2]
(Supplemental Fig. 1).
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Fig. 1  Genome-wide high-content siRNA screening identifies
modulators of APP metabolism. a Schematic representation of APP,
showing the point in the sequence at which the fluorescent proteins (cherry and YFP) were inserted. b Representative fluorescence
microscopy images, showing HEK293 cells transfected with doubletagged APP (cherry-APP-YFP) and stained with Hoechst reagent.
Scale bar 10 µm. c Representative fluorescence microscopy images
showing the impact of siRNA transfection (non-targeting, siAPP or
siPSEN1) on the mCherry and YFP intensities. Scale bar 100 µm. d
Quantification of the relative mean fluorescence intensity of mCherry

and YFP signals per cell after siRNA transfection. Histograms indicate the mean ± SD values. *p < 0.05, non-parametric test. e Mean
fluorescence intensity variations (log2 fold-change) of the YFP signal obtained after genome-wide siRNA screening in triplicate. f Mean
fluorescence intensity variations (log2 fold-change) of the mCherry
signal obtained after genome-wide siRNA screening in triplicate.
The mCherry signal was used to determine the 5% hits exhibiting the
strongest variations (in red; 2.5% showing an upregulation and 2.5%
showing a downregulation). g The best 10 canonical-pathways identified after pathway enrichment analysis using IPA

Genome‑wide, high‑content siRNA screening

for 30 min for staining and cell fixation. Lastly, the cells
were stored in D-PBS, and images were acquired at 405,
488 and 561 nm with an InCell Analyser 6000 high-resolution automated confocal microscope. One field per well
was read from the B1 well to the O24 well in a horizontal,
serpentine acquisition mode with a 20× objective.

The SiGENOME SMARTpool siRNA library (targeting the
18,107 genes of the whole human genome) was screened in
HEK293 cells stably over-expressing a mCherry-APP695wtYFP. Briefly, 50 nl of 10 µM solutions of each siRNA
were first transferred to 384-well microtiter plates using an
Echo 555 liquid handler. Next, 10 µl of D-PBS containing
0.1 µl of lipofectamine™ RNAiMax were then distributed
using a BioTEK EL406 Washer Dispenser. After a 30-min
incubation at room temperature (enabling the transfectant
complex reaction), 40 µl of HEK293-mCherry-APP695wtYFP cells were distributed onto the plates using a BioTEK
EL406 Washer Dispenser, in order to obtain a final density
of 3000 cells per well. The microplates were incubated for
3 days at 37 °C. The cells were then incubated with 5 µg/ml
of Hoechst 33,342 at 37 °C with 5% CO2 (v/v) for 30 min.
After removal of the cell medium, 10% formalin was added
to each well and plates were incubated at room temperature

HCS quantification and analysis
Customized image analysis software (Columbus 2.7, PerkinElmer) was used for the image analysis and the quantification. Hoechst staining was used for the segmentation of
both nuclei and cell. Next, the mean fluorescence intensity
of each mCherry and YFP signals in the cytoplasm were
quantified. The mean fluorescence intensity of each signals
were then normalized to the fold-change based on the nontargeting siRNA in the same plate. To evaluate the impact
of each siRNA, an average of 1000 cells was analyzed per
run (n = 3). For the quality control of HTS, we used strictly
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standardized mean difference with more than 3 of betascore of two positive control (siRNA-APP and siRNA-PS1,
n = 14 each per plate) (Supplemental Fig. 1).
Pathway analysis
Ingenuity Pathway Analysis (IPA; Ingenuity Systems/
Qiagen, Redwood City, USA) was used to map lists of
significant genes to gene ontology groups and biological
pathways. An Ingenuity ‘core analysis’ based on the Ingenuity Pathway Knowledge Base (gene only) was performed
(2015 release) considering only molecules and/or relationships experimentally observed (direct and indirect relationships) in human (stringent filter).
CSF biomarker datasets
CSF samples were obtained from the Knight-ADRC
(N = 893), ADNI (N = 394, the Biomarkers for Older Controls at Risk for Dementia (BIOCARD) (N = 182), Mayo
Clinic (N = 433), Lund University (Swedish) (N = 293),
University of Pennsylvania (Penn) (N = 164), University of
Washington (N = 375).
Cases were diagnosed with dementia of the Alzheimer’s
type (DAT) according to the NINCDS-ADRDA. Control
individuals were evaluated using the same criteria and
showed no symptoms of cognitive impairment. All participants provided written informed consent and the ethics committee approved the informed consent procedure
(IRB ID #: 201105364). 787 additional samples with biomarker data used in the analyses were obtained from the
ADNI database (adni.loni.usc.edu). CSF in all studies
was collected in a standardized manner. Briefly, CSF (20–
35 ml) was collected at 8:00 AM after overnight fasting, as
described previously [10, 11]. LPs (L4/L5) were performed
by a trained neurologist using a 22-gauge Sprotte spinal
needle. Samples were gently inverted to avoid gradient
effects, briefly centrifuged at low speed to pellet any cellular elements, and aliquoted (500 μl) into polypropylene
tubes before freezing at −84 °C. Biomarker measurements
within each study were conducted using internal standards
and controls to achieve consistency and reliability. However, differences in the measured values between studies
were observed which are likely due to differences in the
antibodies and technologies used for quantification (standard ELISA with Innotest for Knight-ADRC, UW, Swedish, German, and Mayo versus Luminex with AlzBio3 for
ADNI-1, ADNI-2, BIOCARD and Penn), ascertainment
and/or handling of the CSF after collection. CSF Aβ42 and
ptau181 values were log transformed in order to approximate a normal distribution. Because the CSF biomarker
values were measured using two different platforms (standard ELISA with Innotest and Luminex with AlzBio3), we
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did not combine the raw data. For the combined analyses,
we standardized the mean of the log-transformed values
from each dataset to zero. No significant differences in
the transformed and standardized CSF values were found
between cohorts. We also performed meta-analyses for
the most significant SNPs by combining the P values for
each independent dataset using METAL. No major differences were found between the joint-analyses and the
meta-analyses.
Cell culture, transfections, and Western blotting (WB)
HEK293 cell lines were maintained in 1:1 DMEM F12/
Opti-MEM supplemented with 10% fetal bovine serum,
penicillin, and streptomycin at 37 °C in a humidified
atmosphere with 5% CO2. Prior to transfection, cells
were plated at a density of ~70%. transient transfection of
FERMT2 cDNA (cloned into a pcDNA4 vector; GeneArt)
was performed using Fugene HD (Invitrogen) according to the manufacturer’s instructions. For WB, cells were
washed with PBS and solubilized in ice-cold lysis buffer
(Tris 1 M pH 7.4; NaCl 1.5 M; Nonidet P-40 0.1%; SDS
10%; sodium orthovanadate 100 mM; sodium deoxycholate 0.5%; 1× complete protease inhibitor mixture, Roche
Applied Sciences). Cell extracts (5–20 μg) were analyzed
using SDS-PAGE and the antibodies listed. For WB and
immunofluorescence analysis, the following antibodies were used: hFERMT2 (GTX84507, GeneTex), amyloid precursor protein C-Terminal (A8717, Sigma), actin
(A2066, Sigma), β-amyloid 6E10 (SIG-39320, Biolegends), ATPase (Na+–K+) alpha subunit (a5, DSHB), Rab4
(PA3-912, Thermo Scientific Pierce), Alzheimer precursor
protein A4 clone 22C11 (MAB348, Millipore). For siRNA
transfection, we used Dharmacon siRNA, non-targeting
(D0018100105) and siFermt2 (J01275305, J01275306,
J01276307, J01275308 and L01275300). Secreted Aβ and
sAPP fragments were analyzed with an AlphaLISA, as
described previously [15].
Primary neuronal cultures
Primary mixed cortical and hippocampal neuronal cultures were obtained from P0 rats, according to previously
described procedures [16]. Briefly, hippocampi and cortices were isolated from newborn rats, and neurons were
dissociated by trypsin digestion. Neurons were plated on
poly-l-lysine-coated coverslips or six-well plates, and
were incubated with minimal essential medium (MEM)
supplemented with 10% fetal bovine serum, Glutamax,
MEM vitamins and penicillin/streptomycin (Life Technologies), according to the manufacturer’s instructions.
After 24 h, neurons were transferred into serum-free Neurobasal-A medium supplemented with B27 (Gibco, Life
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Technologies), Glutamax and uridine-deoxyfluorouridine
for 14 days of in vitro culture. Lentivirus transductions
were performed (MOI = 4) used Mission shRNA vectors (Sigma), non-targeting (05191520MN) and shFermt2
(TRCN0000191859).
Immunofluorescence
The immunofluorescence procedure has been described
previously [5]). In brief, cells were washed with PBS,
fixed in PBS containing 4% paraformaldehyde for 20 min
at room temperature, and then permeabilized with 0.25%
(v/v) Triton X-100 in PBS for 10 min. After blocking in
1% (w/v) bovine serum albumin (BSA), cells were incubated for 2 h at room temperature with primary antibodies diluted 1/100 in PBS 1% BSA. The cells were then
washed 3 times with PBS. Appropriate secondary antibodies (diluted 1/400) were applied. After washing, coverslips
were mounted on slides.
For the APP internalization assay, cells were incubated with
6E10 antibody for 1 h at 4 °C in ice-cold Dulbecco’s modified
Eagle’s medium supplemented with 1% (w/v) bovine serum
albumin and then washed and incubated at 37 °C for the times
indicated. Cells were fixed as described above.
Cell surface biotinylation
HEK293-APP695WT cells or primary neuronal cultures
were transfected in 100 mm dishes. After 48 h of transfection, cell surface proteins were biotinylated using sulfoNHS-SS-biotin, as per the supplier’s recommendations
(Cell Surface Protein Isolation Kit, Pierce). Briefly, cells
were incubated with cold PBS containing sulfo-NHS-SSbiotin for 30 min at 4 °C, with gentle rocking. Cells were
then lysed and immunoprecipitated with streptavidin beads.
Precipitated proteins were eluted from the avidin beads
with loading buffer containing 50 mM DTT, heated for
5 min at 95 °C, and analyzed by WB.
Statistical analysis
The robustness of the replicates between the 3 screens was
assessed using the standard deviation (SD). In average, the
SD was of 11.5% (±7.3%) for the 16,658 genes and 12.4%
(±8.1%) for the 832 hits. Only 661 genes exhibited experiments with an SD superior of 25% for the 16,658 genes
(54 in the 832 list). Associations between the CSF Aβ42
level and the genetic variants were analyzed as previously
reported [7]. Our analysis included a total of 5,815,690
imputed and genotyped variants. We used Plink to analyze
the SNPs’ associations with CSF biomarker levels. Age,
gender, site, and the three principal component factors for
the population structure were included as covariates.
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Results
Systematic high‑content screening for genes
that modulate APP metabolism
To identify modulators of APP metabolism, we developed
a cell-based, high-content assay for the rapid detection and
quantification of intracellular APP fragments in HEK293
cells stably over-expressing a mCherry-APP695WT-YFP
(Fig. 1a, b, Supplemental Fig. 1). After customization for
automatic image processing, we screened a genome-wide
bank of 18,107 human siRNAs (SMARTpool) by analyzing the impact of transfection in our HEK293 model (in
a 384-well plate format). For quality control procedures,
the siRNA-PSEN1 and siRNA-APP (Fig. 1c, d) were
used to calculate the strictly standardized mean difference (denoted as β in Supplemental Fig. 1). The complete
screen was performed in triplicate, and only plates with
β > 3 were analyzed (98.5%) as recommended in highcontent screening (HCS) guidelines [2]. This procedure
led us to select 17,354 siRNAs. Furthermore, experiments
in which less than 300 cells per well were analyzable were
excluded (mean ± standard deviation cell count per well
for the whole HCS experiment: 795 ± 345). The impact of
16,653 siRNA transfections on APP metabolism was then
assessed, and the mean variation in both mCherry and YFP
signals was normalized against the fluorescence intensity
of non-targeting siRNA. It is noteworthy that transfection of siRNA targeting genes already known to modulate
APP metabolism (ADAM10, PSEN1, BACE1 and SORL1)
showed significant variations for mCherry and YFP signals,
compared with non-targeting siRNA (Supplemental Fig. 2).
Because YFP fluorescence is detected weakly, due to its
rapid turnover at the membrane [21], it limited the detection of a down-variation for this signal (Fig. 1e). Thus,
we decided to focus on the mCherry signal as the main
read-out for selecting the 5% of hits showing the strongest variations (2.5% upregulated and 2.5% down-regulated)
(Fig. 1f). In all, 832 hits with a potential impact on APP
metabolism were selected (Fig. 1f; Supplemental Table 1).
In average, the standard deviation was of 12.4% (±8.1%)
for the 832 hits.
Starting from this list of genes, we investigated potential protein–protein interaction networks by using Ingenuity Pathway Analysis (IPA) software (http://www.ingenuity.com/products/ipa). This hypothesis-free approach
described a complex interactive network that was primarily centered on APP (Supplemental Fig. 3). APP was the
protein with the highest number of interactions with other
proteins in the network—indicating that our HCS approach
efficiently detected proteins known to interact with APP.
Gene enrichment analysis (using IPA) of the 832 hits identified 10 significantly over-represented pathways; notably,
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Fig. 2  Cross-correlations between HCS and GWAS data. a Mean
variations in mCherry fluorescence intensity after the silencing of
genes associated with the AD risk in the IGAP’s meta-analysis.
Eight genes (in red) were included in the best 5% variations, based
on the HCS data. b Impact of the silencing of the 8 hits on the Aβ1X secretion level in the medium of the HEK293-mCherry-APP-YFP

cell line. Histograms indicate mean ± SD. *p < 0.05, non-parametric
test. c Validation of FERMT2 silencing after transfection with the
siRNA-FERMT2 SMARTpool used in HCS. d Representative fluorescence microscopy images and quantification showing the impact
of FERMT2 silencing on mCherry and YFP intensity based on HCS
data. Scale bar 10 µm

dermatan and chondroitin sulfate biosynthesis (p = 0.0007)
is involved in the composition of the extracellular matrix
and the glycosylation of proteins like APP (Fig. 1g). All the
other pathways were signaling pathways mainly involving
integrin, paxillin or receptor tyrosine kinase signaling (Supplemental Fig. 4). These pathways (axogenesis; neuron and
neurite development; cell–cell junction maintenance; cell
morphogenesis and projection; and integrin-mediated signaling) have been already implicated in the modulation of
Aβ secretion [3].

regulation of APP metabolism. However, only PIRLA
and FERMT2 showed an effect on the Aβ1-x secretion in
HEK293-mCherry-APP695wt-YFP (Fig. 2b). Lastly, to
assess the potential impact of these genes on Aβ peptide
levels in humans, we measured the association between
SNPs in these 8 genes and cerebrospinal fluid (CSF) Aβ42
peptide levels in a large sample (n = 2886) of AD cases
[7]. After gene-wide correction (Bonferroni, p < 0.006),
we found that only SNPs within FERMT2 were associated
with low Aβ42 peptide levels (p = 0.0006; Table 1).
Of note, according to the RNA-Seq transcriptome and
splicing database (http://web.stanford.edu/group/barres_
lab/brain_rnaseq.html), FERMT2 (but not PIRLA) is
expressed in neurons which are the main sources of Aβ in
the brain. Similar results were observed in another database
focusing on hippocampal neurons (http://hipposeq.janelia.
org/; data not shown).
All together, these observations highlighted the potential role of FERMT2 in the AD process via the modulation of APP metabolism and Aβ peptide generation. We
first validated the silencing of FERMT2 after transfection

Identification of FERMT2 as a genetic risk factor
that modulates APP metabolism
We used HCS data to investigate the function of the genes
within the LOAD risk loci recently reported in the IGAP’s
meta-analysis of GWASs [14]. Of the 123 known genes
reaching genome-wide significance, 8 were included in the
top 5% of hits: OR2AE1, GPC2, PVRIG, PILRA, AGFG2,
TRIM35, EPHX2 and FERMT2 (Fig. 2a) suggesting that
these genes could be involved in the AD process via the
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Table 1  The associations
between the eight genes located
in IGAP loci and the CSF Aβ42
concentration (n = 2886 AD
cases)

961

Modulators of APP metabolism in IGAP loci

Association with the CSF Ab42
level*

Chr.

IGAP locus

Gene

GFP log2 foldchange

mCherry log2
fold-change

SNP

β score

p value

7

ZCWPW1

OR2AE1

−0.58

−1.18

rs35649099

−0.01422

0.2026

GPC2
MGC2463
PILRA
AGFG2
8

PTK2B

TRIM35

14

FERMT2

FERMT2

EPHX2

−0.68
1.29

1.17
−0.34
1.84

−0.46
1.19

±0.05

±0.09

±0.04

±0.10

−1.45
1.83

1.43

±0.05

−1.21

±0.08

−1.42

±0.30

±0.34

1.91

1.67

±0.07

±0.32

±0.02

±0.16

±0.16

±0.50

±0.30

±0.28

rs12705074
rs150436753

−0.01702
0.01965

0.0384
0.1215

rs28714213

0.01737

0.0171

rs78951820

−0.03433

0.0247

rs77389621
rs7341557
rs62003531

−0.02716

0.0584

0.02001

0.0160

−0.02745

0.0006

Bold represents significance after correction for multiple testing
* Linear regression, adjusted for age and gender

of the SMARTpool siRNA library used for HCS (Fig. 2c).
FERMT2 knock-down was associated with the accumulation of both mCherry and YFP signals (Fig. 2d). Thus, we
decided to focus on characterizing the impact of FERMT2
on APP metabolism in cell-based models.
FERMT2 modulates APP processing and metabolite
secretion
To rule out a potential off-target effect of the siRNAFERMT2 SMARTpool used for HCS (four different siRNAs), we first validated the mCherry and YFP signal variations associated with FERMT2 silencing by assessing the
effect of each siRNA-FERMT2 independently (n = 4).
Three siRNA-FERMT2 were associated with an increase in
both mCherry and YFP signals, which was consistent with
the effect observed when using the siRNA pool (Supplemental Fig. 5).
To further evaluate the impact of FERMT2 silencing
on APP metabolism, we quantified mature and immature forms of APP and the various metabolites of APP. In
the HEK293 cell line stably over-expressing APP695WT
(HEK293-APP695WT), we observed that a strong increase in
mature APP levels was associated with the accumulation of
all the APP-derived substrates for α-, β- and γ-secretases
(C83 and C99 intracellular C-terminal fragments of APP
produced, respectively, by α- and β-secretases, as well as
APPα, sAPPβ and Aβ secretions) (Fig. 3a). Again, similar results were obtained using different siRNA-FERMT2
sequences (Supplemental Fig. 6).
Next, we assessed the impact of FERMT2 silencing on endogenous APP metabolism in HEK293. As
observed in HEK293-APP695WT cells, FERMT2 silencing resulted in a significant increase in mature APP levels
(Fig. 3b). It is noteworthy that mature APP levels also rose

after transfection of siRNA-FERMT2 into the HEK293mCherry-APP695wt-YFP cell line (Supplemental Fig. 7)—
showing that the mechanisms were consistent in our cell
models expressing APP695WT in the presence or absence of
mCherry and YFP tags.
Lastly, we confirmed the increase in neuron levels of
mature APP after lentiviral transduction with shRNA
against FERMT2 in a primary neuronal culture (PNC)
endogenously expressing APP (Fig. 3c). Taken as a whole,
these results show that FREMT2 silencing (using either
siRNA or shRNA) controls the mature APP levels in various models overexpressing (or not) APP.
FERMT2 expression controls cell surface levels of APP
A large body of evidence suggests that APP is mainly
cleaved by secretases at or near the plasma membrane. Since
FERMT2 silencing reportedly increases the amount of CD39
and CD73 at the cell surface [18], we looked at whether
FERMT2 can interfere with mature APP levels by promoting APP trafficking to the cell surface. If so, this would be
consistent with our previous observation in which FERMT2
silencing appeared to be associated with a general increase
in mature APP levels, but did not change immature APP
levels in total cell extracts. We addressed this hypothesis
more specifically by performing extracellular biotinylation
experiments; these revealed that FERMT2 silencing strongly
increased mature APP levels at the cell surface in HEK293APP695wt cells (Fig. 4a). Conversely, the over-expression
of FERMT2 was associated with low mature APP levels at
the cell surface (Fig. 4b). This observation was validated in
HEK293 and PNCs (both of which endogenously expressed
APP): FERMT2 silencing was systematically associated
with more abundant mature APP in cell-surface-biotinylated
fractions (Fig. S7 and Fig. 4c, respectively).
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Fig. 3  Characterization of the impact of FERMT2 on APP metabolism. a Impact of FERMT2 silencing on APP metabolism in the
HEK293-APP695WT cell line. Cells transiently transfected with
siFERMT2 or non-targeting siRNA were analyzed by WB using
anti-APP C-terminal, anti-FERMT2 or anti-actin antibodies. sAPPα,
sAPPβ and Aβ1-X secreted into conditioned medium were assayed
using an AlphaLISA. ma. APP, mature APP; im. APP, immature APP.

Densitometric analyses and WB quantifications from three independent experiments are shown. Histograms indicate the mean ± SD. a.u.,
arbitrary units. *p < 0.05, non-parametric test. b Impact of FERMT2
silencing on the mature APP levels in HEK293 cells endogenously
expressing APP. c Quantification of mature and immature APP levels
after lentiviral transduction with shRNA against FERMT2 in a primary neuronal culture endogenously expressing APP

FERMT2 silencing inhibits APP degradation
and promotes APP recycling at the plasma membrane

internalization). A similar observation was made at 40 min
(32 ± 9 and 13 ± 7%, respectively). These data suggest
that FERMT2 lowered lysosomal degradation of APP by
favoring the recycling route and thus boosting cell surface
levels of APP. Inhibition of β3-integrin reportedly promotes
the activation of a RAB4-regulated pathway that (for example) diverts receptor tyrosine kinases (such as the VEGFR)
from the degradative route back to the plasma membrane
[4]. In order to establish whether a similar mechanism was
operating for APP, we measured the effect of FERMT2
silencing on the APP recycling rate (i.e., the proportion of
internalized APP colocalized with Rab4). We observed an
increase in the proportion of Rab4+/APP+ endosomes;
this indicated the induction of the APP recycling and was
concordant with the above-mentioned accumulation of APP
at the cell surface (Fig. 5d, e). Importantly, Rab4 expression did not change after siRNA-FERMT2 transfection.
Lastly, we found that co-transfection of siRNA-FERMT2
with Rab4A-specific siRNA abolished the accumulation
of mature APP (Fig. 5f). These data show that Rab4A is
required for the induction of APP recycling after FERMT2
silencing. Taken as a whole, our results suggest that by
facilitating APP recycling after endocytosis, FERMT2 controls the pool of mature APP available for cleavage by α-,
β- and γ-secretases.

Since FERMT2 silencing reportedly enhances cell-surface CD39/CD73 levels by promoting their recycling to
the plasma membrane [18], we also looked at whether
FERMT2 has a similar effect on APP. To this end, we first
explored the time course of APP degradation by using the
alkalinizing drug bafilomycin A1 (BafA1) to block transport from late endosomes to lysosomes. We found that
siFERMT2 significantly lowered the accumulation of
mature APP upon BafA1 treatment (Fig. 5a)—suggesting
that FERMT2 silencing may lead to a reduction in APP
degradation by lysosomes.
We next assessed the impact of FERMT2 silencing on
APP internalization. After incubation of HEK293-APP695wt
cells with 6E10 antibody at 4 °C, the time course of 6E10APP complex endocytosis was monitored via immunofluorescence (Fig. 5b, c). After 20 min at 37 °C, APP was
rapidly internalized into small vesicles at all levels of
FERMT2 expression. Although internalization was unaffected, the remaining APP staining in vesicles was more
intense in cells under-expressing FERMT2 than in control cells (respectively, 47 ± 16 versus 19 ± 9% of the
initial APP staining observed at the cell surface before

13

Acta Neuropathol (2017) 133:955–966

963

Fig. 4  FERMT2 expression
controls the cell surface level
of mature APP. a Cell-surfacebiotinylated proteins from
HEK293-APP695WT cells
transiently transfected with
siFERMT2 or non-targeting
siRNA. Cell extracts were
precipitated with immobilized
avidin and analyzed by WB
using antibodies against APP,
FERMT2, actin (an intracellular
marker), and Na–K-ATPase
α1 (a cell surface marker). ma.
APP, mature APP; im. APP,
immature APP. Densitometric
analyses and WB quantifications from three independent
experiments are shown. Histograms indicate the mean ± SD.
a.u., arbitrary units. *p < 0.05,
non-parametric test. b Cellsurface-biotinylated proteins
from HEK293-APP695WT cells
transiently transfected with
FERMT2 cDNA or empty
vector (Mock). c Cell-surfacebiotinylated proteins from
primary neuronal culture after
lentiviral transduction with
shRNA against FERMT2 or
non-targeting shRNA

Discussion
One can legitimately hypothesize that at least some of the
genetic risk factors identified in GWASs have a role in APP
metabolism and Aβ production. However, APP metabolism
is a complex process and the underlying mechanisms have
not been fully characterized yet. Literature data on these

risk factors provide indirect clues but clearly cannot ascribe
these genes with a genuine impact at a particular step in
the pathophysiology of APP processing. Furthermore, a
conventional gene-by-gene cell biology approach did not
appear to be time- or cost-effective for investigating the
123 genes located within the GWAS-defined susceptibility
loci. Hence, we developed an HCS assay for empirically
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Fig. 5  FERMT2 silencing inhibits APP degradation and promotes
APP recycling at the plasma membrane. a HEK293-APP695WT cells
transiently transfected with siFERMT2 or non-targeting siRNA were
treated with bafilomycin A1 (BafA1, 50 nM) for the indicated times.
Cell extracts were then analyzed by WB. Densitometric analyses and
mature APP levels for three independent experiments are shown.
Graphs indicate the mean ± SD. *p < 0.05, non-parametric test. b
The time course of APP endocytosis and degradation was indirectly
visualized by internalization of 6E10 antibody. Cells were incubated
with 6E10 antibody at 4 °C for 1 h. The temperature was then shifted
to 37 °C, and cells were processed for immunofluorescence at the

indicated times. Scale bar 10 µm. c Relative fluorescence intensity
from 6E10 staining, showing the time course of APP degradation. d
A zoom-in (the square in b) for the indicated times (0 and 20 min
at 37 °C). Co-staining with anti-Rab4 antibody was used to visualize the APP within Rab4-positive endosomes involving in recycling. e
Co-localization of 6E10 staining with Rab4 staining, as a guide to the
APP level within recycling endosomes at the indicated times. f Cells
transiently transfected with anti-FERMT2 in the presence or absence
of siRab4. Extracts were analyzed by WB using anti-APP C-terminal,
anti-FERMT2, anti-Rab4 or anti-actin antibodies

testing multiple GWAS-identified genes and identifying
modulators of APP metabolism.
Our genome-wide siRNA screening gave us an overview
of the different factors likely to affect APP metabolism and
thus enabled us to select the most significant APP modulators (i.e., the 5% throughout the genome showing the
strongest variations). From among a total of 832 modulators, we identified 8 genes associated with the AD risk in
the largest yet GWAS meta-analysis (the IGAP). Importantly, our approach is not fully exhaustive and it is impossible to exclude that genes involved in APP metabolism are
localized outside of the peak defined by the GWAS but regulated by SNP associated with AD risk. Similarly, focusing
on the 5% strongest variations may lead to exclude some
genes of interest. For instance, although SORL1 was not
included in the 832 best hits, under-expression of this gene

had significant impact on mCherry and YFP signals when
compared with non-targeting siRNA. Moreover, SNPs
localized within SORL1 showed an association with the
CSF Aβ42 level (p = 0.007).
To validate the potential impact of these genes on APP
metabolism in vivo, we assessed the association between
SNPs in these genes and the CSF Aβ42 level in 2886 AD
cases. Only FERMT2 was associated with significantly
low levels of Aβ42 (p = 0.0006) after correction for multiple testing. The SNP rs62003531 most strongly associated
with the Aβ42 level was in strong linkage disequilibrium
(r2 = 0.77) with the sentinel SNP rs17125944 (found to
be associated with the AD risk in the IGAP’s GWAS metaanalysis). It is noteworthy that this sentinel polymorphism
was also associated with Aβ42 levels (p = 0.03)—suggesting that both these SNPs represent the same genetic signal.
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Taken as a whole, these data indicate that FERMT2 regulates APP metabolism in general and Aβ loads in particular. Accordingly, we observed that FERMT2 silencing led
to an increase in mature APP levels and Aβ secretion. Since
we also observed that APP recycling was promoted by
FERMT2 silencing through Rab4A-positive endosomes, our
data strongly suggest that FERMT2 regulates APP recycling
and its presence at the cell surface. The extracellular domain
of APP is reportedly involved in cell–matrix adhesion and
facilitates cell–cell adhesion via transcellular interactions
[17]. Interaction between APP and integrin is required for
adequate neurite outgrowth and contact guidance [24, 27].
Moreover, abnormal cleavage of APP might impair the protein’s functions in cell adhesion and migration [22]. Hence,
the regulation of cell adhesion may be important in APP
metabolism. Furthermore, FERMT2 expression is required
for cell adhesion; recruitment of the focal adhesion kinase
FAK and p130CAS is required for β3 integrin signaling
[19, 25]. Several lines of evidence have established that
integrin signaling controls the trafficking of other receptors and cargos [4]. For instance, inhibition of β3-integrin
might promote the activation of a Rab4-regulated pathway
that (for example) diverts receptor tyrosine kinases (such
as the VEGFR) from their degradation route back to the
plasma membrane [20]. These data suggest that FERMT2
has an integrin-dependent impact on mature APP levels via
a similar mechanism. It is noteworthy that some of the main
regulators of integrin signaling (e.g., β3-integrin, Src, paxillin and p130Cas) were also identified as modulators of APP
metabolism in our HCS analysis (Supplemental Fig. 4).
Although FERMT2 expression appears to control cell
surface levels of APP (which might modulate cell adhesion), our data also indicate that a FERMT2 under-expression may favor Aβ production. Interestingly, by using
another independent, systematic approach, we have already
suggested that low FERMT2 expression might contribute to the development of AD [8]. We reported that the
rs7143400-T allele (associated with an increase in the AD
risk and located within the FERMT2 3′ untranslated region
[3′-UTR]) creates a perfect seed for miR-4504. Co-transfection of the rs7143400-T allele and miR-4504 resulted
in lower luciferase activity (relative to the rs7143400-G
allele co-transfected with the same miRNA). This observation indicated that a functional SNP within the FERMT2
3′-UTR region is associated with an increase in the AD
risk and a potential miR-dependent decrease in FERMT2
expression. It is noteworthy that the rs7134400 SNP is in
perfect linkage disequilibrium (r2 = 1) with rs62003531,
which exhibited the most significant association with the
CSF level of Aβ42. Taken as a whole, our data suggest that
the rs7134400 T allele is associated with an increased AD
risk by lowering FERMT2 expression; in turn, this disrupts
APP metabolism and favors Aβ production.

965

Lastly, we recently highlighted the fact that several
GWAS-defined genes already known to be involved in
the focal adhesion pathway (Fak, Cass4 and EPHA1) are
potential modulators of Tau toxicity in Drosophila [9].
Since genetic risk factors involved in cell adhesion signaling have been associated with Aβ production or Tau toxicity, we suggest that the characterization of these mechanisms should deepen our understanding of the link between
amyloid and Tau in the AD process. FERMT2 might be
located at the interface between these two hallmarks pathological processes because it has already been described as a
modulator of Tau toxicity in Drosophila [23].
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